Literature DB >> 21778764

Effect of cystamine on blood pressure and vascular characteristics in spontaneously hypertensive rats.

M Engholm1, A Eftekhari, G Chwatko, E Bald, M J Mulvany.   

Abstract

BACKGROUND: Tissue transglutaminase (t-TG) has been implicated in small artery remodelling. The aim of this study was to determine if cystamine, an inhibitor of t-TG, could reduce blood pressure in spontaneously hypertensive rats (SHR) and if so to what extent this is mediated through small arteries.
METHODS: In vitro inhibition of t-TG, with cystamine, was studied in organ culture and wire myograph setups in small mesenteric arteries obtained from SHR. In vivo treatment with cystamine (80 mg/kg/day) or amlodipine (10 mg/kg/day) was performed with osmotic pumps in adult SHR, and hemodynamic parameters determined with telemetry. Plasma concentrations of cystamine were determined with a liquid chromatography setup. Small arteries were harvested following administration of cystamine, and structural as well as functional characteristics were determined.
RESULTS: SHR small arteries showed inward remodelling following in vitro activation. Administration of cystamine caused attenuation of the inward remodelling induced by activation. In vivo administration of cystamine caused a 9 ± 2 mm Hg reduction in blood pressure, but with no detectable alterations in small artery structure.
CONCLUSION: t-TG is potentially involved in vascular remodelling of SHR small arteries and results support a possible role for t-TG in blood pressure control.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21778764     DOI: 10.1159/000327773

Source DB:  PubMed          Journal:  J Vasc Res        ISSN: 1018-1172            Impact factor:   1.934


  11 in total

1.  Transglutaminase activity is decreased in large arteries from hypertensive rats compared with normotensive controls.

Authors:  Humphrey G Petersen-Jones; Kyle B Johnson; Kiyotaka Hitomi; Nathan R Tykocki; Janice M Thompson; Stephanie W Watts
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-01-16       Impact factor: 4.733

2.  Transglutaminase 2 promotes PDGF-mediated activation of PDGFR/Akt1 and β-catenin signaling in vascular smooth muscle cells and supports neointima formation.

Authors:  Maria Nurminskaya; Kelly E Beazley; Elizabeth P Smith; Alexey M Belkin
Journal:  J Vasc Res       Date:  2015-01-22       Impact factor: 1.934

3.  Tissue transglutaminase contributes to the pathogenesis of preeclampsia and stabilizes placental angiotensin receptor type 1 by ubiquitination-preventing isopeptide modification.

Authors:  Chen Liu; Wei Wang; Nicholas Parchim; Roxanna A Irani; Sean C Blackwell; Baha Sibai; Jianping Jin; Rodney E Kellems; Yang Xia
Journal:  Hypertension       Date:  2013-11-04       Impact factor: 10.190

4.  Increased tissue transglutaminase activity contributes to central vascular stiffness in eNOS knockout mice.

Authors:  Sung Mee Jung; Simran Jandu; Jochen Steppan; Alexey Belkin; Steven S An; Alina Pak; Eric Y Choi; Daniel Nyhan; Mark Butlin; Kayla Viegas; Alberto Avolio; Dan E Berkowitz; Lakshmi Santhanam
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-07-19       Impact factor: 4.733

5.  Brief serotonin exposure initiates arteriolar inward remodeling processes in vivo that involve transglutaminase activation and actin cytoskeleton reorganization.

Authors:  Christopher A Foote; Jorge A Castorena-Gonzalez; Marius C Staiculescu; Philip S Clifford; Michael A Hill; Gerald A Meininger; Luis A Martinez-Lemus
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-11-13       Impact factor: 4.733

6.  Involvement of transglutaminase 2 and voltage-gated potassium channels in cystamine vasodilatation in rat mesenteric small arteries.

Authors:  Morten Engholm; Estéfano Pinilla; Susie Mogensen; Vladimir Matchkov; Elise Røge Hedegaard; Hua Chen; Michael J Mulvany; Ulf Simonsen
Journal:  Br J Pharmacol       Date:  2016-01-27       Impact factor: 8.739

7.  Transglutaminase 2 in human diseases.

Authors:  Zsuzsa Szondy; Ilma Korponay-Szabó; Robert Király; Zsolt Sarang; Gregory J Tsay
Journal:  Biomedicine (Taipei)       Date:  2017-08-25

Review 8.  Inflammation, Autoimmunity, and Hypertension: The Essential Role of Tissue Transglutaminase.

Authors:  Chen Liu; Rodney E Kellems; Yang Xia
Journal:  Am J Hypertens       Date:  2017-08-01       Impact factor: 2.689

Review 9.  Cystamine and cysteamine as inhibitors of transglutaminase activity in vivo.

Authors:  Thomas M Jeitner; John T Pinto; Arthur J L Cooper
Journal:  Biosci Rep       Date:  2018-09-05       Impact factor: 3.840

10.  Transglutaminase is a Critical Link Between Inflammation and Hypertension.

Authors:  Renna Luo; Chen Liu; Serra E Elliott; Wei Wang; Nicholas Parchim; Takayuki Iriyama; Patrick S Daugherty; Lijian Tao; Holger K Eltzschig; Sean C Blackwell; Baha M Sibai; Rodney E Kellems; Yang Xia
Journal:  J Am Heart Assoc       Date:  2016-06-30       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.